Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• Liposomes are utilized as drug delivery systems (DDSs) and can be modified with targeting ligands like peptides.
• Current methods for evaluating DDS targeting involve extensive in vitro and in vivo studies.
• A need exists for an efficient and accurate screening system for targeted DDS carriers.

Purpose of the Study:

• To establish and validate an ex vivo screening system for assessing the interaction between targeting ligands and their receptors.
• To evaluate the utility of this ex vivo system for screening DDS carriers modified with targeting moieties.
• To correlate ex vivo findings with in vitro and in vivo targeting abilities of peptide-modified liposomes.

Main Methods:

• Liposomes were modified with an integrin αvβ3-targeting peptide (C16Y-L).
• In vitro cellular uptake studies were conducted using colon26 cells.
• Ex vivo immunohistochemical analysis was performed on colon26 tumor sections.
• In vivo intratumoral localization studies were conducted after intravenous injection.

Main Results:

• C16Y-L liposomes demonstrated higher cellular uptake in colon26 cells compared to control liposomes.
• Ex vivo analysis showed specific binding of C16Y-L to colon26 tumor sections.
• In vivo studies revealed accumulation of C16Y-L in tumor tissue and vasculature.
• Ex vivo and in vivo analyses showed a strong correlation in targeting ability.

Conclusions:

• The developed ex vivo system provides an easy, rapid, and high-precision method for screening targeted DDS carriers.
• This ex vivo approach correlates well with in vivo conditions, aiding in the development of effective DDSs.
• The ex vivo peptide-modified liposomal analysis is a valuable tool for pre-clinical evaluation of DDS targeting efficacy.